Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Westbrook

Otolaryngology El Paso, TX Medical Doctor

NPI 1013170299 CMS profile 1304058

1500 N Mesa St, El Paso, TX 79902

Open in the dashboard

General payments

$16,936

182 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Westbrook of El Paso, TX is reported in the CMS Open Payments database as having received $16,936 across 182 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,243 41
2024 General $1,699 35
2023 General $1,043 40
2022 General $2,154 18
2021 General $7,941 25
2020 General $2,453 17
2019 General $402 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Westbrook
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Benjamin Westbrook were reported at $1,243. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Benjamin Westbrook Otolaryngology median Middle half National median
2019 $402 $194 $82–$512 $163
2020 $2,453 $118 $42–$280 $114
2021 $7,941 $167 $63–$444 $132
2022 $2,154 $216 $84–$545 $149
2023 $1,043 $235 $93–$588 $160
2024 $1,699 $280 $111–$699 $164
2025 $1,243 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $4,123 7 payments
  2. Intersect ENT, Inc. $2,760 11 payments
  3. Inspire Medical Systems, Inc. $2,646 68 payments
  4. Stryker Corporation $2,501 18 payments
  5. Medical Device Business Services, Inc. $1,112 3 payments
  6. Aerin Medical Inc. $778 11 payments
  7. Medtronic, Inc. $504 9 payments
  8. Vertex Pharmaceuticals Incorporated $332 14 payments
  9. Merz North America, Inc. $289 5 payments
  10. Integra LifeSciences Corporation $245 2 payments
  11. Other $1,646 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,229 171 payments
  2. Travel and Lodging $5,207 10 payments
  3. Education $3,500 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System Surgery $3,500 1 payment
  2. PROPEL $2,442 8 payments
  3. SINUVA $2,398 7 payments
  4. ENTELLUS - XPRESS ENT DILATION SYSTEM $2,084 10 payments
  5. INSPIRE $1,552 64 payments
  6. Inspire Upper Airway Stimulation System $1,094 4 payments
  7. Da Vinci Surgical System Surgery $623 6 payments
  8. RHINAER STYLUS $519 7 payments
  9. VIVAER STYLUS $519 7 payments
  10. JOURNAVX $332 14 payments
  11. Other $5,252 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

737

Median for Otolaryngology: 297

Drug cost

$13,913

Median for Otolaryngology: $6,314

Branded share of claims

3.5%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluticasone Propionate Generic 245 $4,662
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 26 $2,723
Ipratropium Bromide Generic 37 $1,363
Azelastine Hcl Generic 39 $1,287
Doxycycline Hyclate Generic 53 $829
Ofloxacin Generic 13 $590
Calcitriol Generic 23 $563
Famotidine Generic 27 $532
Ibuprofen Generic 100 $499
Oxycodone Hcl Generic 88 $335

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 116 billing codes

Paid by Medicare

$134,433

Medicare's payments for the services billed

Medicare patients

303

Average age 74

Services billed

1,150

162 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 35%
Ischemic heart disease 27%
Chronic kidney disease 27%
Depression 24%
COPD 20%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

182 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record